Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer

Autores
Labanca, Estefania; Yang, Jun; Shepherd, Peter D. A.; Wan, Xinhai; Starbuck, Michael W.; Guerra, Leah D.; Anselmino, Nicolás; Bizzotto, Juan Antonio; Dong, Jiabin; Chinnaiyan, Arul M.; Ravoori, Murali K.; Kundra, Vikas; Broom, Bradley M.; Corn, Paul G.; Troncoso, Patricia; Gueron, Geraldine; Logothethis, Christopher J.; Navone, Nora
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
BACKGROUND: No curative therapy is currently available for metastatic prostate cancer (PCa). The diverse mechanisms of progression include fibroblast growth factor (FGF) axis activation. OBJECTIVE: To investigate the molecular and clinical implications of fibroblast growth factor receptor 1 (FGFR1) and its isoforms (α/β) in the pathogenesis of PCa bone metastases. DESIGN, SETTING, AND PARTICIPANTS: In silico, in vitro, and in vivo preclinical approaches were used. RNA-sequencing and immunohistochemical (IHC) studies in human samples were conducted. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: In mice, bone metastases (chi-square/Fisher's test) and survival (Mantel-Cox) were assessed. In human samples, FGFR1 and ladinin 1 (LAD1) analysis associated with PCa progression were evaluated (IHC studies, Fisher's test). RESULTS AND LIMITATIONS: FGFR1 isoform expression varied among PCa subtypes. Intracardiac injection of mice with FGFR1-expressing PC3 cells reduced mouse survival (α, p < 0.0001; β, p = 0.032) and increased the incidence of bone metastases (α, p < 0.0001; β, p = 0.02). Accordingly, IHC studies of human castration-resistant PCa (CRPC) bone metastases revealed significant enrichment of FGFR1 expression compared with treatment-naïve, nonmetastatic primary tumors (p = 0.0007). Expression of anchoring filament protein LAD1 increased in FGFR1-expressing PC3 cells and was enriched in human CRPC bone metastases (p = 0.005). CONCLUSIONS: FGFR1 expression induces bone metastases experimentally and is significantly enriched in human CRPC bone metastases, supporting its prometastatic effect in PCa. LAD1 expression, found in the prometastatic PCa cells expressing FGFR1, was also enriched in CRPC bone metastases. Our studies support and provide a roadmap for the development of FGFR blockade for advanced PCa. PATIENT SUMMARY: We studied the role of fibroblast growth factor receptor 1 (FGFR1) in prostate cancer (PCa) progression. We found that PCa cells with high FGFR1 expression increase metastases and that FGFR1 expression is increased in human PCa bone metastases, and identified genes that could participate in the metastases induced by FGFR1. These studies will help pinpoint PCa patients who use fibroblast growth factor to progress and will benefit by the inhibition of this pathway.
Fil: Labanca, Estefania. University of Texas; Estados Unidos
Fil: Yang, Jun. University of Texas; Estados Unidos
Fil: Shepherd, Peter D. A.. University of Texas; Estados Unidos
Fil: Wan, Xinhai. University of Texas; Estados Unidos
Fil: Starbuck, Michael W.. University of Texas; Estados Unidos
Fil: Guerra, Leah D.. University of Texas; Estados Unidos
Fil: Anselmino, Nicolás. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales; Argentina
Fil: Bizzotto, Juan Antonio. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales; Argentina
Fil: Dong, Jiabin. University of Texas; Estados Unidos
Fil: Chinnaiyan, Arul M.. University Of Michigan Medical School; Estados Unidos
Fil: Ravoori, Murali K.. University of Texas; Estados Unidos
Fil: Kundra, Vikas. University of Texas; Estados Unidos
Fil: Broom, Bradley M.. University of Texas; Estados Unidos
Fil: Corn, Paul G.. University of Texas; Estados Unidos
Fil: Troncoso, Patricia. University of Texas; Estados Unidos
Fil: Gueron, Geraldine. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales; Argentina
Fil: Logothethis, Christopher J.. University of Texas; Estados Unidos
Fil: Navone, Nora. University of Texas; Estados Unidos
Materia
BONE METASTASIS
FIBROBLAST GROWTH FACTOR RECEPTOR 1
LADININ 1
PROSTATE CANCER
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/173304

id CONICETDig_f5fccde4ce0b7ef18b832d4d9782d1da
oai_identifier_str oai:ri.conicet.gov.ar:11336/173304
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate CancerLabanca, EstefaniaYang, JunShepherd, Peter D. A.Wan, XinhaiStarbuck, Michael W.Guerra, Leah D.Anselmino, NicolásBizzotto, Juan AntonioDong, JiabinChinnaiyan, Arul M.Ravoori, Murali K.Kundra, VikasBroom, Bradley M.Corn, Paul G.Troncoso, PatriciaGueron, GeraldineLogothethis, Christopher J.Navone, NoraBONE METASTASISFIBROBLAST GROWTH FACTOR RECEPTOR 1LADININ 1PROSTATE CANCERhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3BACKGROUND: No curative therapy is currently available for metastatic prostate cancer (PCa). The diverse mechanisms of progression include fibroblast growth factor (FGF) axis activation. OBJECTIVE: To investigate the molecular and clinical implications of fibroblast growth factor receptor 1 (FGFR1) and its isoforms (α/β) in the pathogenesis of PCa bone metastases. DESIGN, SETTING, AND PARTICIPANTS: In silico, in vitro, and in vivo preclinical approaches were used. RNA-sequencing and immunohistochemical (IHC) studies in human samples were conducted. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: In mice, bone metastases (chi-square/Fisher's test) and survival (Mantel-Cox) were assessed. In human samples, FGFR1 and ladinin 1 (LAD1) analysis associated with PCa progression were evaluated (IHC studies, Fisher's test). RESULTS AND LIMITATIONS: FGFR1 isoform expression varied among PCa subtypes. Intracardiac injection of mice with FGFR1-expressing PC3 cells reduced mouse survival (α, p < 0.0001; β, p = 0.032) and increased the incidence of bone metastases (α, p < 0.0001; β, p = 0.02). Accordingly, IHC studies of human castration-resistant PCa (CRPC) bone metastases revealed significant enrichment of FGFR1 expression compared with treatment-naïve, nonmetastatic primary tumors (p = 0.0007). Expression of anchoring filament protein LAD1 increased in FGFR1-expressing PC3 cells and was enriched in human CRPC bone metastases (p = 0.005). CONCLUSIONS: FGFR1 expression induces bone metastases experimentally and is significantly enriched in human CRPC bone metastases, supporting its prometastatic effect in PCa. LAD1 expression, found in the prometastatic PCa cells expressing FGFR1, was also enriched in CRPC bone metastases. Our studies support and provide a roadmap for the development of FGFR blockade for advanced PCa. PATIENT SUMMARY: We studied the role of fibroblast growth factor receptor 1 (FGFR1) in prostate cancer (PCa) progression. We found that PCa cells with high FGFR1 expression increase metastases and that FGFR1 expression is increased in human PCa bone metastases, and identified genes that could participate in the metastases induced by FGFR1. These studies will help pinpoint PCa patients who use fibroblast growth factor to progress and will benefit by the inhibition of this pathway.Fil: Labanca, Estefania. University of Texas; Estados UnidosFil: Yang, Jun. University of Texas; Estados UnidosFil: Shepherd, Peter D. A.. University of Texas; Estados UnidosFil: Wan, Xinhai. University of Texas; Estados UnidosFil: Starbuck, Michael W.. University of Texas; Estados UnidosFil: Guerra, Leah D.. University of Texas; Estados UnidosFil: Anselmino, Nicolás. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales; ArgentinaFil: Bizzotto, Juan Antonio. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales; ArgentinaFil: Dong, Jiabin. University of Texas; Estados UnidosFil: Chinnaiyan, Arul M.. University Of Michigan Medical School; Estados UnidosFil: Ravoori, Murali K.. University of Texas; Estados UnidosFil: Kundra, Vikas. University of Texas; Estados UnidosFil: Broom, Bradley M.. University of Texas; Estados UnidosFil: Corn, Paul G.. University of Texas; Estados UnidosFil: Troncoso, Patricia. University of Texas; Estados UnidosFil: Gueron, Geraldine. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales; ArgentinaFil: Logothethis, Christopher J.. University of Texas; Estados UnidosFil: Navone, Nora. University of Texas; Estados UnidosElsevier2021-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/173304Labanca, Estefania; Yang, Jun; Shepherd, Peter D. A.; Wan, Xinhai; Starbuck, Michael W.; et al.; Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer; Elsevier; European Urology Oncology; 5; 2; 11-2021; 164-1752588-9311CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S2588931121001826?via%3Dihubinfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.euo.2021.10.001info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-11-05T09:46:35Zoai:ri.conicet.gov.ar:11336/173304instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-11-05 09:46:36.208CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer
title Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer
spellingShingle Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer
Labanca, Estefania
BONE METASTASIS
FIBROBLAST GROWTH FACTOR RECEPTOR 1
LADININ 1
PROSTATE CANCER
title_short Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer
title_full Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer
title_fullStr Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer
title_full_unstemmed Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer
title_sort Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer
dc.creator.none.fl_str_mv Labanca, Estefania
Yang, Jun
Shepherd, Peter D. A.
Wan, Xinhai
Starbuck, Michael W.
Guerra, Leah D.
Anselmino, Nicolás
Bizzotto, Juan Antonio
Dong, Jiabin
Chinnaiyan, Arul M.
Ravoori, Murali K.
Kundra, Vikas
Broom, Bradley M.
Corn, Paul G.
Troncoso, Patricia
Gueron, Geraldine
Logothethis, Christopher J.
Navone, Nora
author Labanca, Estefania
author_facet Labanca, Estefania
Yang, Jun
Shepherd, Peter D. A.
Wan, Xinhai
Starbuck, Michael W.
Guerra, Leah D.
Anselmino, Nicolás
Bizzotto, Juan Antonio
Dong, Jiabin
Chinnaiyan, Arul M.
Ravoori, Murali K.
Kundra, Vikas
Broom, Bradley M.
Corn, Paul G.
Troncoso, Patricia
Gueron, Geraldine
Logothethis, Christopher J.
Navone, Nora
author_role author
author2 Yang, Jun
Shepherd, Peter D. A.
Wan, Xinhai
Starbuck, Michael W.
Guerra, Leah D.
Anselmino, Nicolás
Bizzotto, Juan Antonio
Dong, Jiabin
Chinnaiyan, Arul M.
Ravoori, Murali K.
Kundra, Vikas
Broom, Bradley M.
Corn, Paul G.
Troncoso, Patricia
Gueron, Geraldine
Logothethis, Christopher J.
Navone, Nora
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv BONE METASTASIS
FIBROBLAST GROWTH FACTOR RECEPTOR 1
LADININ 1
PROSTATE CANCER
topic BONE METASTASIS
FIBROBLAST GROWTH FACTOR RECEPTOR 1
LADININ 1
PROSTATE CANCER
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv BACKGROUND: No curative therapy is currently available for metastatic prostate cancer (PCa). The diverse mechanisms of progression include fibroblast growth factor (FGF) axis activation. OBJECTIVE: To investigate the molecular and clinical implications of fibroblast growth factor receptor 1 (FGFR1) and its isoforms (α/β) in the pathogenesis of PCa bone metastases. DESIGN, SETTING, AND PARTICIPANTS: In silico, in vitro, and in vivo preclinical approaches were used. RNA-sequencing and immunohistochemical (IHC) studies in human samples were conducted. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: In mice, bone metastases (chi-square/Fisher's test) and survival (Mantel-Cox) were assessed. In human samples, FGFR1 and ladinin 1 (LAD1) analysis associated with PCa progression were evaluated (IHC studies, Fisher's test). RESULTS AND LIMITATIONS: FGFR1 isoform expression varied among PCa subtypes. Intracardiac injection of mice with FGFR1-expressing PC3 cells reduced mouse survival (α, p < 0.0001; β, p = 0.032) and increased the incidence of bone metastases (α, p < 0.0001; β, p = 0.02). Accordingly, IHC studies of human castration-resistant PCa (CRPC) bone metastases revealed significant enrichment of FGFR1 expression compared with treatment-naïve, nonmetastatic primary tumors (p = 0.0007). Expression of anchoring filament protein LAD1 increased in FGFR1-expressing PC3 cells and was enriched in human CRPC bone metastases (p = 0.005). CONCLUSIONS: FGFR1 expression induces bone metastases experimentally and is significantly enriched in human CRPC bone metastases, supporting its prometastatic effect in PCa. LAD1 expression, found in the prometastatic PCa cells expressing FGFR1, was also enriched in CRPC bone metastases. Our studies support and provide a roadmap for the development of FGFR blockade for advanced PCa. PATIENT SUMMARY: We studied the role of fibroblast growth factor receptor 1 (FGFR1) in prostate cancer (PCa) progression. We found that PCa cells with high FGFR1 expression increase metastases and that FGFR1 expression is increased in human PCa bone metastases, and identified genes that could participate in the metastases induced by FGFR1. These studies will help pinpoint PCa patients who use fibroblast growth factor to progress and will benefit by the inhibition of this pathway.
Fil: Labanca, Estefania. University of Texas; Estados Unidos
Fil: Yang, Jun. University of Texas; Estados Unidos
Fil: Shepherd, Peter D. A.. University of Texas; Estados Unidos
Fil: Wan, Xinhai. University of Texas; Estados Unidos
Fil: Starbuck, Michael W.. University of Texas; Estados Unidos
Fil: Guerra, Leah D.. University of Texas; Estados Unidos
Fil: Anselmino, Nicolás. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales; Argentina
Fil: Bizzotto, Juan Antonio. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales; Argentina
Fil: Dong, Jiabin. University of Texas; Estados Unidos
Fil: Chinnaiyan, Arul M.. University Of Michigan Medical School; Estados Unidos
Fil: Ravoori, Murali K.. University of Texas; Estados Unidos
Fil: Kundra, Vikas. University of Texas; Estados Unidos
Fil: Broom, Bradley M.. University of Texas; Estados Unidos
Fil: Corn, Paul G.. University of Texas; Estados Unidos
Fil: Troncoso, Patricia. University of Texas; Estados Unidos
Fil: Gueron, Geraldine. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales; Argentina
Fil: Logothethis, Christopher J.. University of Texas; Estados Unidos
Fil: Navone, Nora. University of Texas; Estados Unidos
description BACKGROUND: No curative therapy is currently available for metastatic prostate cancer (PCa). The diverse mechanisms of progression include fibroblast growth factor (FGF) axis activation. OBJECTIVE: To investigate the molecular and clinical implications of fibroblast growth factor receptor 1 (FGFR1) and its isoforms (α/β) in the pathogenesis of PCa bone metastases. DESIGN, SETTING, AND PARTICIPANTS: In silico, in vitro, and in vivo preclinical approaches were used. RNA-sequencing and immunohistochemical (IHC) studies in human samples were conducted. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: In mice, bone metastases (chi-square/Fisher's test) and survival (Mantel-Cox) were assessed. In human samples, FGFR1 and ladinin 1 (LAD1) analysis associated with PCa progression were evaluated (IHC studies, Fisher's test). RESULTS AND LIMITATIONS: FGFR1 isoform expression varied among PCa subtypes. Intracardiac injection of mice with FGFR1-expressing PC3 cells reduced mouse survival (α, p < 0.0001; β, p = 0.032) and increased the incidence of bone metastases (α, p < 0.0001; β, p = 0.02). Accordingly, IHC studies of human castration-resistant PCa (CRPC) bone metastases revealed significant enrichment of FGFR1 expression compared with treatment-naïve, nonmetastatic primary tumors (p = 0.0007). Expression of anchoring filament protein LAD1 increased in FGFR1-expressing PC3 cells and was enriched in human CRPC bone metastases (p = 0.005). CONCLUSIONS: FGFR1 expression induces bone metastases experimentally and is significantly enriched in human CRPC bone metastases, supporting its prometastatic effect in PCa. LAD1 expression, found in the prometastatic PCa cells expressing FGFR1, was also enriched in CRPC bone metastases. Our studies support and provide a roadmap for the development of FGFR blockade for advanced PCa. PATIENT SUMMARY: We studied the role of fibroblast growth factor receptor 1 (FGFR1) in prostate cancer (PCa) progression. We found that PCa cells with high FGFR1 expression increase metastases and that FGFR1 expression is increased in human PCa bone metastases, and identified genes that could participate in the metastases induced by FGFR1. These studies will help pinpoint PCa patients who use fibroblast growth factor to progress and will benefit by the inhibition of this pathway.
publishDate 2021
dc.date.none.fl_str_mv 2021-11
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/173304
Labanca, Estefania; Yang, Jun; Shepherd, Peter D. A.; Wan, Xinhai; Starbuck, Michael W.; et al.; Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer; Elsevier; European Urology Oncology; 5; 2; 11-2021; 164-175
2588-9311
CONICET Digital
CONICET
url http://hdl.handle.net/11336/173304
identifier_str_mv Labanca, Estefania; Yang, Jun; Shepherd, Peter D. A.; Wan, Xinhai; Starbuck, Michael W.; et al.; Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer; Elsevier; European Urology Oncology; 5; 2; 11-2021; 164-175
2588-9311
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S2588931121001826?via%3Dihub
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.euo.2021.10.001
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1847977116762636288
score 13.121305